WO2024121383A1 - Nouvelles compositions - Google Patents

Nouvelles compositions Download PDF

Info

Publication number
WO2024121383A1
WO2024121383A1 PCT/EP2023/084886 EP2023084886W WO2024121383A1 WO 2024121383 A1 WO2024121383 A1 WO 2024121383A1 EP 2023084886 W EP2023084886 W EP 2023084886W WO 2024121383 A1 WO2024121383 A1 WO 2024121383A1
Authority
WO
WIPO (PCT)
Prior art keywords
skin
postbiotic
composition
preparation
lautus
Prior art date
Application number
PCT/EP2023/084886
Other languages
English (en)
Inventor
Riccardo SFRISO
Aline HUEBER
Remo CAMPICHE
Beatrice TASSONE
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2024121383A1 publication Critical patent/WO2024121383A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/005—Preparations for sensitive skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to novel topical compositions comprising postbiotics obtained from Paenibacillus lautus and the use of such compositions in balancing the skin microbiome.
  • the human skin is the biggest organ of the human body, and it is the barrier that separates the body from the outer environment.
  • the surface of the skin is colonized by millions of microorganisms, also known as the skin microbiome.
  • Said microbiome includes all kinds of microbiota such as e.g. bacteria, fungi, viruses, archaea, mites (for review, see Byrd et al., Nature Reviews Microbiology, vol.16, 2018, 143-155).
  • the commensal microbiota are in constant interaction amongst each other as well as with the immune system of the host organism to fight against pathogenic microbes, such as e.g. Staphylococcus aureus.
  • the present invention is directed to said postbiotics in dried or liquid form and compositions comprising said postbiotics as well as for the use thereof for the preparation of cosmetic, particularly topical, compositions for improvement/ maintenance of a healthy skin barrier, protection of commensal skin microflora and prevention of detrimental effects, such as e.g. inflammation, as associated with skin diseases including but not limited to psoriasis, atopic dermatitis and allergy, as well as non disease-related conditions, such as skin itching, skin aging, particularly improvement/ maintenance of a healthy skin barrier, protection of commensal skin microflora and prevention of negative effects as associated with e.g. psoriasis, atopic dermatitis, cellular apoptosis, itching, skin allergy, as induced by pathogenic microbiota such as e.g. Staphylococcus aureus.
  • the present invention is directed to a postbiotic obtained from Paenibacillus lautus.
  • postbiotic as used herein and in line with the definition of the International Probiotics Association (ISAPP) (Salminen et al., Nature Reviews Gastraoenterology & Hepatology, 18, 649-667, 2021) is defined as a preparation of inanimate/ non-viable microorganisms, i.e. of Paenibacillus lautus, including its components or metabolites that confer a health benefit to the host when applied to the skin microflora (skin microbiota) as disclosed herein, particularly by reducing (decreasing) pathogenic species such as e.g. strains of Staphylococcus aureus.
  • ISAPP International Probiotics Association
  • P. lautus postbiotic is used interchangeably herein, meaning that P. lautus is the starting material (progenitor microorganism) for the postbiotic.
  • strains of P. lautus can be grown by any method known to the skilled person.
  • the P. lautus biomass can be recovered from the fermentation broth during the exponential growth phase and/or during the stationary phase, by any methods known in the art including but not limited to centrifugation, extraction, maceration, separation, concentration and/or filtration followed by inactivation of the bacteria.
  • the P. lautus postbiotic is a dried extract comprising polar and non-polar components, with about 10% being non-polar and about 90% being polar components, including but not limited to sugars, free amino acids, ions, lipids, particularly with sugar monomers and dimers being in the range of less than 1%, free amino acids in the range of less than 10% and ions in the range of less than 20%, all based on total ingredients in said dried extract.
  • the present invention is related to a preparation of non-viable microorganism selected from Paenibacillus lautus in the form of a dried extract, particularly wherein said preparation is used for topical applications, such as used in a topical composition.
  • topical applications such as used in a topical composition.
  • compositions that are used in topical applications.
  • said dried extract does not comprise or only comprises minor traces of sugars such as rhamnose, glucose and/or fucose, wherein "minor traces" as defined herein means not more than 0.5% for each sugar based on total ingredients in said dried extract.
  • the P. lautus postbiotic is a liquid formulation, comprising the dried extract as defined above dissolved in a suitable solvent, including but not limited to 1,3 propanediol (PDO), glycerol, ethanol, water, preferably PDO.
  • a suitable solvent including but not limited to 1,3 propanediol (PDO), glycerol, ethanol, water, preferably PDO.
  • the liquid formulation as defined herein comprises a range of 2 to 5% dried extract in the solvent, particularly a range of 2-5% dried extract in PDO, such as e.g. about 2, 2.5, 2.8, 3, 3.2, 3.5, 3.8, 4, 4.2, 4.5, 4.8 or 5% dried extract in PDO, including chemically produced PDO or biologically-derived PDO.
  • the present invention is directed to a composition, particularly a cosmetic composition, comprising a P. lautus postbiotic as defined herein, such as e.g. the dried extract or the liquid formulation as defined herein, wherein the final concentration of the P. lautus postbiotic in the composition, particularly cosmetic composition, is in the range of 0.001 to 0.01%.
  • a composition particularly a cosmetic composition
  • the term "topical" means external application to keratinous substances, which are in particular the skin, scalp, eyelashes, eyebrows, nails, mucous membranes and hair, preferably the skin.
  • the term "commensal skin microflora” as used herein includes resident microbiota including but not limited to Staphylococcus epidermidis, Staphylococcus hominis, Cutibacterium acnes, Corynebacterium striatum, Micrococcus luteus, Micrococcus yunnanensis, (see for example Byrd et al. 2018, Nat Rev Microbiol 16:143).
  • a "maintenance or improvement of the commensal skin microflora” includes but is not limited to protection of the commensal skin microflora, keeping or fostering a diverse microbiome free from dysbiosis, and in homeostasis with the skin.
  • maintenance/improvement of the skin barrier or “balancing the skin microbiome” or “maintenance or promotion of the skin barrier” are used interchangeably herein and means keeping a healthy skin barrier that protects the organism from excess water loss (low transepidermal water loss), maintain the expression of key markers responsible for a healthy skin barrier, and maintaining a skin microbiome in homeostasis with the skin.
  • the present invention relates to the use of said P. lautus postbiotic or a composition, particularly cosmetic composition, comprising said postbiotic, with a final concentration of at least about 0.001% in said composition, particularly cosmetic composition, as skin protective agent, i.e. an agent which exhibits protective activity on the commensal skin microflora.
  • skin protective agent i.e. an agent which exhibits protective activity on the commensal skin microflora.
  • the present invention is directed to the use of a postbiotic and/or composition comprising said postbiotic according to the present invention for balancing the skin microbiome, maintenance and improvement of the skin barrier, prevention of detrimental effects to the skin due to colonization of the skin by pathogenic microbes, such as in particular colonization by Staphylococcus aureus.
  • the invention relates to a P. lautus postbiotic and/or a composition, particularly a cosmetic composition, comprising said postbiotic as defined herein for improving/ maintaining the self-defense mechanism of the skin, in particular the self-defense mechanism towards pathogenic microbes including but not limited to Staphylococcus aureus, as well as to methods or use of said postbiotic and/or compositions comprising said postbiotic for improving of such skin self-defense mechanism, said method or use comprising contacting the skin with a composition, particularly cosmetic composition, comprising said P. lautus postbiotic as defined herein.
  • the invention relates to a P. lautus postbiotic and/or a composition, particularly a cosmetic composition, comprising said postbiotic as defined herein for reducing and/or abolishing cellular skin apoptosis, as well as to methods or use of said postbiotic and/or compositions comprising said postbiotic for reduction and/or abolishing of said cellular skin apoptosis, said method or use comprising contacting the skin with a composition, particularly cosmetic composition, comprising said P. lautus postbiotic as defined herein.
  • the invention relates to a P. lautus postbiotic and/or composition, particularly cosmetic composition, comprising said postbiotic as defined herein for improvement and maintenance of commensal skin microflora, in particular wherein the balance is not shifted towards Staphylococcus aureus, as well as to method or use of said postbiotic and/or compositions comprising said postbiotic for maintenance and improvement of said commensal skin microflora, said method or use comprising contacting the skin with a composition, particularly cosmetic composition, comprising said P. lautus postbiotic as defined herein.
  • the invention relates to a P. lautus postbiotic and/or composition, particularly cosmetic composition, comprising said postbiotic as defined herein for reducing and/or abolishing colonization or adhesion of pathogenic skin microbes, in particular Staphylococcus aureus, to the skin surface as well as to methods or use of said postbiotic and/or compositions comprising said postbiotic for reduction and/or abolishing of said colonization/adhesion, said method or use comprising contacting the skin with a composition, particularly cosmetic composition, comprising said P. lautus postbiotic as defined herein.
  • the invention relates to a P. lautus postbiotic and/or composition, particularly cosmetic composition, comprising said postbiotic as defined herein for reducing and/or abolishing itch sensation and/or inflammation as associated with atopic dermatitis, psoriasis, allergy etc., as well as to method or use of said postbiotic and/or compositions comprising said postbiotic for reduction and/or abolishing of said itching or inflammatory events associated with said diseases.
  • improving or maintenance of the self-defense mechanism of the skin means maintaining and fostering a healthy skin barrier, particularly the stratum corneum.
  • maintaining and fostering the skin innate immunity e.g. anti-microbial peptides
  • maintaining and fostering the skin innate immunity e.g. anti-microbial peptides
  • reducing and/or abolishing of cellular skin apoptosis means preventing excess apoptosis due to environmental insult, such as e.g. including but not limited to an excess apoptosis due to an increase of pathogenic microbes like Staphylococcus aureus.
  • Apoptosis is commonly measured by counting apoptotic cells and compare the number to a control without these apoptotic events.
  • reducing and/or abolishing of colonization or adhesion of pathogenic skin microbes means preventing the excess adhesion of pathobionts, such as but not limited to Staphylococcus aureus, and to maintain a healthy and divers skin microbiome.
  • skin inflammation includes a heating and burning sensation accompanied with skin reddening/erythema, on molecular level associated with the increased synthesis and release of inflammatory markers such as but not limited to cytokines, matrix-metalloproteases, and serine proteases.
  • reducing and/or abolishing of itching or inflammation/skin reddening associated with atopic dermatitis, psoriasis, allergy means keeping cellular and molecular reactions stimulating or enhancing inflammation and its associated sensations (e.g. itch, burning, stinging) in check or lowering it.
  • the postbiotic according to the present invention is a liquid formulation consisting essentially of the postbiotic as defined herein in the form of a dried extract and PDO, wherein the percentage of the postbiotic is in the range of 2 to 5% by weight.
  • the term "consists essentially of” as used according to the present invention means that the total amount of ingredients within the extract, formulation or composition ideally sum up to 100 wt.-%. It is however not excluded that small amounts of impurities or additives may be present in the extract/formulation/composition, with the proviso that the total amount of such impurities is preferably less than about 5 wt.-%, more preferably less than about 3, 2, 1 wt.-% and which are e.g. introduced via the respective raw materials and/or processes used.
  • impurities and “additives” are used interchangeably and refer to co-ingredients within the inventive extract, formulations or compositions and that are present therein in an amount of less than 5 wt.-% based on all ingredients present in said dried extracts, formulations or compositions.
  • Prevention includes not only total prevention but also delaying the onset of, lessening the severity of an incident/symptoms of the condition, and/or increasing the length of time between recurrence of the incidence/condition.
  • Preferred products in all embodiments of the present invention are cosmetic compositions comprising the postbiotic as described herein.
  • Said compositions preferably comprise water and at least one further agent selected from the group consisting of surfactants, emulsifiers, thickeners and oils.
  • the invention is also directed to cosmetic products/ cosmetic compositions comprising water and at least one agent selected from the group consisting of surfactants, emulsifiers, thickeners and oils, wherein the composition furthermore comprises the P. lautus postbiotic according to the present invention in a final concentration in the range of 0.001%, preferably in a range of between 0.001 to 0.01%, such as e.g. in a range of at least about 0.0095, 0.009, 0.0085, 0.008, 0.0075, 0.007, 0.0065, 0.006, 0.0055, 0.005, 0.0045, 0.004, 0.0035, 0.003, 0.0025, 0.002, 0.015, 0.01% by weight.
  • the water content in said cosmetic compositions according to the present invention is selected in the range from 30 to 90 wt.-%, from 40 to 90 wt.-%, from 45 to 90 wt.-% or from 50 to 90 wt.-%, based on the total weight of the composition. Further suitable ranges are from 30 to 75 wt.-%, from 30 to 70 wt.-%, from 30 to 60 wt.-% and from 40 to 60 wt.-%.
  • the P. lautus postbiotic and/or composition comprising said postbiotic according to the present invention can also be used in combination with traditional preservatives to improve the preservative activity thereof.
  • the cosmetic products/ compositions according to the present invention are in particular topically applied to mammalian keratinous tissue such as in particular to human or animal skin or the human or animal scalp and hair.
  • the present invention is directed to a P. lautus postbiotic and/or composition
  • a P. lautus postbiotic and/or composition comprising said postbiotic as defined herein for the use as topical product, i.e. cosmetic product topically applied to the human or animal keratinous tissues including skin, scalp and hair.
  • cosmetic product refers to cosmetic compositions as defined under the heading "Kosmetika” in Rompp Lexikon Chemie, 10th edition 1997, Georg Thieme Verlag Stuttgart, New York as well as to cosmetic compositions as disclosed in A. Domsch, "Cosmetic Compositions", Verlag fur chemische Industrie (ed. H. Ziolkowsky), 4 th edition, 1992.
  • Suitable surfactants, emulsifiers, thickeners, and oils for the purpose of the present inventions are all surfactants, emulsifiers, thickeners, and oils commonly used in cosmetic applications and which are e.g. listed in the International Cosmetic Ingredient Dictionary & Handbook by Personal Care Product Council (http://www.personalcarecouncil.org/), accessible by the online INFO BASE (http://online.personalcarecouncil.org/jsp/Home.jsp), without being limited thereto.
  • the products according to the present invention are generally prepared by admixing a postbiotic/composition comprising said postbiotic according to the present invention in an amount selected in the range 0.005 to 2 wt.-%, more preferably in the range of about 0.01 to 1 wt.-%, most preferably in the range of about 0.03 to 0.75 wt.-% such as in the range of 0.05 to 0.5 wt.-%, based on the total weight of the product with a suitable carrier.
  • the cosmetic products according to the present invention preferably further comprise a physiologically acceptable medium, that is to say a medium compatible with keratinous substances, such as the skin, mucosa, and keratinous fibers.
  • a physiologically acceptable medium is a cosmetically acceptable carrier.
  • cosmetic carrier refers to all carriers and/or excipients and/or diluents conventionally used in cosmetic compositions. As used herein, it can be understood to be a physiologically acceptable medium, i.e. a medium compatible for the intended use such as e.g. with keratinous substances, such as the skin, mucous membranes, and keratinous fibers.
  • the carrier consists furthermore of at least about 30 wt.-%, more preferably of at least about 40 wt.-%, most preferably of at least about 45, 50, 60, 70, 80, 90 wt.-% of water, such as in particular a range of from 30 to 90 wt.-%, such as from 40 to 90 wt.-%, from 45 to 90 wt.-% or from 50 to 90 wt.-%, based on the total weight of the composition. Further suitable ranges are from 30 to 75 wt.-%, from 30 to 70 wt.-%, from 30 to 60 wt.-% and from 40 to 60 wt.-%.
  • the cosmetic products/ compositions according to the invention are in the form of a suspension or dispersion in solvents or fatty substances, or alternatively in the form of an emulsion or micro emulsion (in particular of O/W- or W/O-type), PIT-emulsion, nano emulsion, multiple emulsion (e. g. O/W/O- or W/O/W-type), pickering emulsion, hydrogel, lipogel, one- or multiphase solution or vesicular dispersion.
  • an emulsion or micro emulsion in particular of O/W- or W/O-type
  • PIT-emulsion nano emulsion
  • multiple emulsion e. g. O/W/O- or W/O/W-type
  • pickering emulsion hydrogel, lipogel, one- or multiphase solution or vesicular dispersion.
  • the cosmetic products/ compositions in accordance with the invention can be in the form of a liquid, lotion, a thickened lotion, a gel, a cream, a milk, an ointment or a paste.
  • the cosmetic products/ compositions according to the invention have a pH in the range of 3-10, preferably in the range of pH of 3-8, most preferred in the range of pH 3.5-7.S.
  • the pH is adjusted by methods known to a person skilled in the art, e.g. by using an acid such as a hydroxy acid including glycolic acid, lactic acid, malic acid, citric acid and tartaric acid or a base such as e.g. sodium or potassium hydroxide or ammonium hydroxide as well as mixtures thereof.
  • said acid if present, is used in an amount of at lowest about 0.0001 wt.-%, such as e.g. in an amount of about 0.01 to 1 wt.-%, in particular in an amount of about 0.01 to 0.5 wt.-%.
  • the amount of the cosmetic composition to be applied to the skin is not critical and can easily be adjusted by a person skilled in the art.
  • the amount is selected in the range of 0.1 to 3 mg/cm 2 skin, such as preferably in the range of 0.1 to 2 mg/cm 2 skin and most preferably in the range of 0.5 to 2 mg/cm 2 skin.
  • the cosmetic products/ compositions according to the present invention are in particular skin care preparations, functional preparations and/or hair care preparations such as most in particularly skin or hair care preparations.
  • the present invention is directed to the use of a P. lautus postbiotic and/or composition comprising said postbiotic as defined herein as skin or hair care preparations, i.e. for the preparation of cosmetical products applied to skin or hair of humans or animals.
  • Examples of skin care preparations are, in particular, light protective preparations (sun care preparations), anti-ageing preparations, preparations for the treatment of photo-ageing, body oils, body lotions, body gels, treatment creams, skin protection ointments, moisturizing preparations such as moisturizing gels or moisturizing sprays, face and/or body moisturizers, as well as skin lightening preparations.
  • light protective preparations unsun care preparations
  • anti-ageing preparations preparations for the treatment of photo-ageing
  • body oils body lotions, body gels, treatment creams, skin protection ointments
  • moisturizing preparations such as moisturizing gels or moisturizing sprays
  • face and/or body moisturizers as well as skin lightening preparations.
  • the skin care preparation is a deodorant, an anti-perspirant, or an anti-acne composition.
  • Examples of functional preparations are cosmetic compositions containing active ingredients such as hormone preparations, vitamin preparations, vegetable extract preparations, anti-ageing preparations, and/or antimicrobial (antibacterial or antifungal) preparations without being limited thereto.
  • hair care preparations which are suitable according to the invention and which may be mentioned are shampoos, hair conditioners (also referred to as hair rinses), hairdressing compositions, hair tonics, hair regenerating compositions, hair lotions, water wave lotions, hair sprays, hair creams, hair gels, hair oils, hair pomades or hair brilliantines. Accordingly, these are always preparations which are applied to the hair and the scalp for a shorter or longer time depending on the actual purpose for which they are used.
  • the hair care preparations according to the invention are supplied as shampoos, these can be clear liquids, opaque liquids (with pearly luster effect), in cream form, gel-like or else in powder form or in tablet form, and as aerosols.
  • the surfactant raw materials on which these shampoos are based can be anionic, cationic, nonionic and amphoteric in nature and also be present in combinations of these substances.
  • the cosmetic compositions according to the present invention are O/W emulsions, W/O emulsions and/or gels such as shower gels or hair gels.
  • a consortium of commensal bacteria at 1.1 x 10 6 CFU/ ml of each bacterium was prepared.
  • the bacteria were Staphylococcus epidermidis, Cutibacterium acnes and Corynebacterium striatum.
  • Labskin (Innovenn Labskin, York, UK) was colonized with 10 CFU of the consortium and incubated at 37°C for 2 hours until Labskin surfaced had dried. Tissues were then treated with various concentrations of a dried extract obtained from Paenibacillus lautus fermentation, i.e. P.
  • Table 1 expression of cytokeratin 1 as detected with immunochemistry.
  • a (%) means difference of expression using the vehicle as compared to the expression using mix I or mix II;
  • S.D. means standard deviation, "a.u.” means arbitrary units. For further details see text.
  • ELISA Human Quantikine®
  • IL-8 a common marker to monitor the therapeutic effect in atopic dermatitis patients
  • IL-23 a common marker connected to psoriasis, wherein both markers are linked to inflammation.
  • Table 2A expression of IL-8 as detected with ELISA.
  • a (%) means difference of expression using the vehicle as compared to the expression using mix I or mix II;
  • S.D means standard deviation.
  • Table 2B expression of IL-23 as detected with ELISA.
  • a (%) means difference of expression using the vehicle as compared to the expression using mix I;
  • S.D. means standard deviation.
  • mix I i.e. P. lautus postbiotic in a final concentration of about 0.01%
  • reduced inflammation measured via reduced expression of inflammation marker IL-23, by more than 50% as compared to application of a control (water).
  • Example 3 Effect of Paenibacillus lautus postbiotic on skin barrier and S. aureus adhesion to the skin surface
  • Filaggrin was visualized with HISTOFINE SIMPLE STAIN AP MULTI alkaline phosphatase (NICHIREI BIOSCIENCES, 414262F) and new fuchsin substrate kit as chromogen (NICHIREI BIOSCIENCES, 415161 F). Nuclei were counter-stained with Mayer's hematoxylin. S. aureus was visualized with Alexa Fluor Plus 555 donkey anti-rabbit (Life Technologies, A32794) and nuclei were counter-stained with DAPI solution (Table 3 and 4). Table 3: expression of filaggrin in the human epidermis model. "A (%)” means difference of expression using the vehicle or mix I as compared to the expression on untreated tissue; "S.D.” means standard deviation; "untreated” means human epidermis without colonization with S. aureus. For further details see text.
  • mix I i.e. P. lautus postbiotic in a final concentration of about 0.01%
  • mix I i.e. P. lautus postbiotic in a final concentration of about 0.01%, resulted in reduced adhesion of S. aureus by more than 70% as compared to application of a control (water).
  • Table 4B apoptotic cells in response to S. aureus colonization on human epidermis as detected with TUNEL staining.
  • a (%) means difference of expression using the vehicle as compared to the expression using mix I;
  • S.D. means standard deviation;
  • untreated means human epidermis treated with mix I but without colonization with S. aureus.
  • mix I i.e. P. lautus postbiotic in a final concentration of about 0.01%
  • Cosmetic formulations in the form of gels, emulsions, shampoo, hair cream, lotion, make-up, toner, after-shave, creams, hand sanitizer are created according to methods known in the art. If not indicated otherwise the pH of the formulations is adjusted to pH 3-7.5 as deemed appropriate.
  • the term "NEW INGREDIENT” refers to Paenibacillus lautus postbiotic, i.e. mix I and mix II in the final concentration as indicated in Table 1.
  • Table 5 Cosmetic gels comprising P. lautus postbiotic. For further details see Example 1.
  • Table 7 0/W emulsions comprising P. lautus postbiotic. Palmitoyl Pentapeptide- 4 is given in [ppm]. For further details see text.
  • Table 8 W/0 emulsions comprising P. lautus postbiotic. Palmitoyl Tripeptide-38 is given in [ppm]. For further details see text.
  • Table 9 0/W emulsion comprising P. lautus postbiotic for facial cream.
  • Table 10 natural lotion comprising P. lautus postbiotic. For further details see text.
  • Table 11 liquid make-up comprising P. lautus postbiotic. For further details see text.
  • Table 12 moisturizing toner comprising P. lautus postbiotic. For further details see text.
  • Table 13 after shave SPF 15 comprising P. lautus postbiotic. For further details see text.
  • Table 14 anti-aging serum comprising P. lautus postbiotic. For further details see text.
  • Table 15 anti-aging cream comprising P. lautus postbiotic. For further details see text.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouvelles compositions topiques contenant des postbiotiques obtenus à partir de Paenibacillus lautus et l'utilisation de telles compositions pour équilibrer le microbiome cutané.
PCT/EP2023/084886 2022-12-09 2023-12-08 Nouvelles compositions WO2024121383A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH14702022 2022-12-09
CH001470/2022 2022-12-09

Publications (1)

Publication Number Publication Date
WO2024121383A1 true WO2024121383A1 (fr) 2024-06-13

Family

ID=89190646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/084886 WO2024121383A1 (fr) 2022-12-09 2023-12-08 Nouvelles compositions

Country Status (1)

Country Link
WO (1) WO2024121383A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101239757B1 (ko) * 2012-11-15 2013-03-06 주식회사 지디 알긴산 분해효소를 생산하는 신규 미생물 페니바실러스 라우투스 ｇｄ－ａ2와 알긴산 분해용 생촉매 및 이를 이용한 알긴산 올리고당의 제조 방법
KR20140055959A (ko) * 2012-10-29 2014-05-09 주식회사 엘지생활건강 항균활성 미생물의 발효 성분을 포함하는 항균 조성물
US20160338979A1 (en) * 2014-01-10 2016-11-24 The Regents Of The University Of California Skin probiotic
WO2021250155A1 (fr) * 2020-06-12 2021-12-16 Dsm Ip Assets B.V. Nouvelle utilisation
KR102449689B1 (ko) * 2022-06-07 2022-09-30 전남대학교 산학협력단 페니바실러스 라우투스 js-1 균주 또는 이의 배양액을 포함하는 항진균용 및 식물병 방제용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140055959A (ko) * 2012-10-29 2014-05-09 주식회사 엘지생활건강 항균활성 미생물의 발효 성분을 포함하는 항균 조성물
KR101239757B1 (ko) * 2012-11-15 2013-03-06 주식회사 지디 알긴산 분해효소를 생산하는 신규 미생물 페니바실러스 라우투스 ｇｄ－ａ2와 알긴산 분해용 생촉매 및 이를 이용한 알긴산 올리고당의 제조 방법
US20160338979A1 (en) * 2014-01-10 2016-11-24 The Regents Of The University Of California Skin probiotic
WO2021250155A1 (fr) * 2020-06-12 2021-12-16 Dsm Ip Assets B.V. Nouvelle utilisation
KR102449689B1 (ko) * 2022-06-07 2022-09-30 전남대학교 산학협력단 페니바실러스 라우투스 js-1 균주 또는 이의 배양액을 포함하는 항진균용 및 식물병 방제용 조성물

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Rompp Lexil<on Chemie", 1997, GEORG THIEME VERLAG, article "Kosmetil<a"
A. DOMSCH: "Cosmetic Compositions", 1992, VERLAG FUR CHEMISCHE INDUSTRIE
BYRD ET AL., NAT REV MICROBIOL, vol. 16, 2018, pages 143
BYRD ET AL., NATURE REVIEWS MICROBIOLOGY, vol. 16, 2018, pages 143 - 155
SALMINEN ET AL., NATURE REVIEWS GASTRAOENTEROLOGY & HEPATOLOGY, vol. 18, 2021, pages 649 - 667
SANMIGUEL ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAP, vol. 61, no. 9, 24 August 2017 (2017-08-24), pages 0074 - 17
YU YANG-YANG ET AL: "Electrochemistry of newly isolated Gram-positive bacteria Paenibacillus lautus with starch as sole carbon source", ELECTROCHIMICA ACTA, ELSEVIER, AMSTERDAM, NL, vol. 411, 15 February 2022 (2022-02-15), XP086994616, ISSN: 0013-4686, [retrieved on 20220215], DOI: 10.1016/J.ELECTACTA.2022.140068 *

Similar Documents

Publication Publication Date Title
CA2557834C (fr) Methode de traitement de la peau au moyen d&#39;extrait de lactobacillus
US11116810B2 (en) Methods for treatment of skin and skin appendages with a linseed extract as an active agent activating the synthesis of antimicrobial peptides
WO2022119895A1 (fr) Procédés et compositions pour le traitement microbien de troubles cutanés
WO2018073278A1 (fr) Composition cosmétique pour prévenir et/ou traiter une odeur corporelle
EP3120850B1 (fr) Niacinamide pour induire la production de peptides antimicrobiens
KR20210029359A (ko) 여드름 개선용 화장료 조성물
WO2024121383A1 (fr) Nouvelles compositions
US20240277782A1 (en) Compositions and methods for microbial treatment of skin disorders
CN116635003A (zh) 用于皮肤障碍的微生物治疗的方法和组合物
EP0909557A1 (fr) Utilisation du miel en tant qu&#39;agent diminuant l&#39;adhésion des micro-organismes
WO2018108973A1 (fr) Fraction oligopeptidique obtenue à partir d&#39;une biomasse de bactérie ou de bactéries appartenant au genre vitreoscilla sp., en tant que principe actif cosmétique
KR20230005810A (ko) 피부 질환의 미생물 치료를 위한 조성물 및 방법
EP4434590A1 (fr) Principe actif cosmétique comprenant un extrait de levure endophytique de type kwoniella mangroviensis et ses utilisations
FI131136B1 (en) The use of ingredients based on Nordic plants to support a healthy skin microbiome
JP7503503B2 (ja) 炎症性成分を有する皮膚または粘膜の罹患を予防および処置するための化合物
KR102487267B1 (ko) 아스타잔틴 복합 성분을 유효성분으로 포함하는 항염증용 화장료 조성물
KR102482157B1 (ko) 황 함유 아미노산이 함유되어 피부 스트레스 개선 효능이 우수한 락토바실러스 혼합배양액을 유효성분으로 함유하는 화장료 조성물
KR102485135B1 (ko) 아스타잔틴 복합 성분을 유효성분으로 포함하는 다기능성 화장료 조성물
WO2020096058A1 (fr) Agent de contrôle des glandes sébacées
WO2023220508A1 (fr) Compositions comprenant des fermentats multifonctionnels de brevibacilla et procédés d&#39;utilisation
KR20240111998A (ko) 민감성 피부 개선용 화장료 조성물
KR20230043873A (ko) 다당류가 풍부한 봄박스 코스타툼 꽃 추출물
KR20130017825A (ko) 참그물바탕말을 이용한 피부 외용제 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23821969

Country of ref document: EP

Kind code of ref document: A1